Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.New River ADHD drug shows promise in phase II
A total of 52 children with ADHD were enrolled in a crossover study that compared NRP104 and Shire Pharmaceuticals’ Adderall XR to placebo in terms of efficacy, duration
A total of 52 children with ADHD were enrolled in a crossover study that compared NRP104 and Shire Pharmaceuticals’ Adderall XR to placebo in terms of efficacy, duration
Forest Laboratories has indicated that the letter came after an FDA review of the company’s response, dated August 2004, to an initial non-approvable letter. The first letter raised
Under the agreement, phase I and II clinical trials will be conducted by the New Approaches to Brain Tumor Therapy CNS Consortium (NABTT) in two different patient populations
These new studies add to the growing body of evidence that support this treatment strategy for treatment-experienced patients, building upon findings from the Fuzeon pivotal trials, TORO-1 and
NeuroVax is a T-cell receptor (TCR) peptide vaccine designed to specifically down-regulate the body’s destructive immune responses observed in multiple sclerosis (MS) patients to alleviate the impact of
This new agreement will use BioFocus’s high throughput screening expertise to discover compounds that ‘hit’ nuclear hormone receptors (NHRs). Under the terms of the agreement, BioFocus will receive
The grant entails a collaborative effort between researchers at Micronics and the Seattle Children’s Research Institute (SCRI), in which a novel primer design method that enables detection of
The letter indicated that Glumetza is approvable pending the completion of discussions about finalizing a manufacturing specification. Biovail anticipates submitting a response to the FDA in the coming
Valeant acquired Tasmar (tolcapone) from Roche and re-launched the product in the US and other countries throughout the rest of the world in the summer of 2004. Tasmar
Four sites have been selected to conduct Samaritan’s trial for HIV-infected patients experiencing resistance to antiretroviral therapy. In addition, internal review boards responsible for protecting study patients have